Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs)
$46.05
neg -0.80
-1.71%
Today's Range: 46.03 - 47.03 | BMY Avg Daily Volume: 11,095,600
Last Update: 06/19/13 - 4:00 PM EDT
Volume: 7,809,066
YTD Performance: 43.76%
Open: $46.60
Previous Close: $46.85
52 Week Range: $30.64 - $49.57
Oustanding Shares: 1,642,551,939
Market Cap: 76,280,112,047
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 6 6 6
Moderate Buy 1 1 1 1
Hold 12 12 13 13
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.38 2.45 2.48 2.48
Latest Dividend: 0.35
Latest Dividend Yield: 3.01%
Dividend Ex-Date: 04/03/13
Price Earnings Ratio: 52.18
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
52.18 53.40 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
20.50% 35.48% 81.73%
GROWTH 12 Mo 3 Yr CAGR
Revenue -17.10 -0.06 -0.02
Net Income -52.50 -0.43 -0.17
EPS -46.30 -0.78 -0.39
Earnings for BMY:
EBITDA 4.77B
Revenue 17.62B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $0.45 $0.46 $1.81 $2.11
Number of Analysts 10 9 13 11
High Estimate $0.47 $0.48 $1.85 $2.42
Low Estimate $0.43 $0.43 $1.78 $1.93
Prior Year $0.48 $0.37 $1.99 $1.81
Growth Rate (Year over Year) -6.87% 24.62% -9.08% 16.57%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Jun 12, 2013 | 3:42 PM EDT

There is going to be a fear of recession if rates keep going up.

By

Doug Kass

 | Jun 11, 2013 | 10:48 AM EDT
At various times last year and in the previous year, U.S. stocks fell violently because of substantive issues in the eurozone.
By

Jim Cramer

 | Jun 3, 2013 | 11:25 AM EDT

Jim Cramer looks at stocks moving on cancer-fighting develompents, in a discussion with Mad Money Research Director Nicole Urken

By

Jim Cramer

 | May 29, 2013 | 7:30 AM EDT

Here we go again: What does this have to do with the price-to-earnings ratio of Bristol Myers?

By

Doug Kass

 | May 28, 2013 | 3:58 PM EDT
How much to sell?

updateUBS Healthcare Conf.

May 21, 2013 | 6:44 AM EDT

UBS Global Healthcare Conference

bullishBristol-Myers upgraded at Leerink

May 17, 2013 | 8:18 AM EDT

BMY was upgraded from Market Perform to Outperform, Leerink Swann said. Cancer product pipeline should drive future growth. 

By

Adam Feuerstein

 | May 16, 2013 | 2:09 PM EDT

<I>TheStreet</I> senior columnist Adam Feuerstein discusses the winners and losers from the research abstracts ahead of the ASCO cancer conference.

bullishBristol-Myers target boosted at Goldman

May 16, 2013 | 8:15 AM EDT

Shares of BMY now seen reaching $48, according to Goldman Sachs. PD-1 data has exceeded expectations. Buy rating. 

By

Adam Feuerstein

 | May 9, 2013 | 9:39 AM EDT

TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.

Bullish Case for the Bonds (TLT)

By

Toni Hansen

 | Jun 20, 2013 | 1:22 AM EDT
Has the TLT finally found support? More importantly, can it hold it? I think there is a case to be made for it... Here i...

Texas's power grid pours on the coal

By

Glenn Williams

 | Jun 19, 2013 | 8:36 PM EDT
Faced with a capacity shortfall and possible energy shortages, Texas power producers dusted off some old plants and put ...

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.